Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17

@antibotter you must have skipped over the ASCO poster presentations where the investigator says ‘further clinical development of DEP CTX is justified’.

And you must have skipped over the bad news webinar business update where the CEO said that the big multinationals want Starpharma to make ‘further investment in clinical studies‘

If the 505(B)(2) route was actually a live option then multiple big pharma would be falling over themselves to licence all three DEP drugs. But they’re not.

You can stop with the disingenuous and misleading ramping of the 505(b)(2) furphy.